Juan de la Haba-Rodriguez

Trop-2 overexpression as a prognostic marker in early triple-negative breast cancer: results from the GEICAM_CIBOMA trial

Trophoblast cell-surface antigen 2 (Trop-2) is a key therapeutic target in metastatic triple-negative breast cancer (TNBC), yet its prognostic significance in early-stage disease remains poorly defined. We evaluated Trop-2 expression and its clinical impact within a sub-cohort of...